Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CODXBullishLegalnews

High materiality7/10

Co-Diagnostics Submits FDA 510(k) for Decentralized Flu A/B & RSV Test

Aug 6, 2026, 9:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory milestones often prompt short-term upside, especially for a niche diagnostics player with a decentralized testing thesis; success could unlock new revenue channels, though clear clearance timing is unknown and execution risk remains.

AI summary

What happened, with direct paths to the underlying reporting

Co-Diagnostics announced a Dual 510(k) premarket submission with a concurrent CLIA Waiver by Application for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument. Supported by 1,400 symptomatic patients across nine U.S. sites and over 10,000 test runs, the filing targets decentralized waived testing and broader access to molecular diagnostics.

FDA 510(k) with CLIA Waiver by Application for Co-Dx PCR Pro.
Test: Flu A/B & RSV multiplex on decentralized point-of-care platform.
Clinical/analytical studies: 1,400 patients across nine sites; 10,000+ tests.
Co-Dx platform enables cloud-based outbreak tracking in near-patient settings.
Milestone aims to expand decentralized molecular testing access and affordability.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Co-Diagnostics Submits FDA 510(k) for Decentralized Flu A/B & RSV Test

Co-Diagnostics Expands TB Test Distribution, Market Opportunities Increase

Co-Diagnostics Expands South Asian Market Reach for PCR Products

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version